Pure Global AI
NCT06357819Completed

INSTI® HCV (Hepatitis C Virus) Antibody Self-Test Contrived Result Interpretation

bioLytical LaboratoriesClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Hepatitis C
Drug/Device/Intervention
INSTI HCV Self Test
Study type
Observational
Intervention type
device
Sponsor & location
Primary sponsor
bioLytical Laboratories
Location
Richmond, Canada
Timeline & enrollment
Phase
N/A
Start date
Oct 12, 2023
End date
Dec 17, 2023
Enrollment
405 participants
Primary outcome

Successful Interpretation of contrived devices

Summary

The purpose of this Interpretation Assessment was to document if lay people,
 non-professional and inexperienced in self-testing, were able to successfully perform the
 steps to use a Hepatitis C Virus (HCV) Self-Test (HCVST) device, without product
 familiarization [demonstration].

ICD-10 classifications
Acute hepatitis CChronic viral hepatitis CViral hepatitisChronic viral hepatitisUnspecified viral hepatitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06357819
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06357819 through Pure Global AI's free database. This phase not specified trial is sponsored by bioLytical Laboratories and is currently Completed. The study focuses on Hepatitis C. Target enrollment is 405 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.